2Carney DN.Lung cancer-time to move on from chemotherapy[J].N Engl J Med,2002,346(2):126-128.
3Hubbard SR,Miller WT.Receptor tyrosine kinases:mechanisms of activation and signaling[J].Curr Opin Cell Biol 2007,19(2):117-123.
4Sakurada A,Shepherd FA,Tsao MS.Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer:impact of primary or secondary mutations[J].Clin Lung Cancer 2006,7(Suppl 14):138-144.
5Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial)[J].J Clin Oncol,2003,21(12):2237-2346.
6Perez-Soler R,Chachoua A,Hammond LA,et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J].J Clin Oncol,2004,22(16):3238-3247.
9Thatcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomized,placebo-controlled,multicentre study (Iressa Survival Evaluation in Lung Cancer)[J].Lancet,2005,366(9465):1527-1537.
10Kelly K,Chansky K,Gaspar LE,et al.Phase III trial of maintenance gefitinib or placebo after concurrent chemoradio therapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer:SWOG S0023[J].J Clin Oncol,2008,26(15):2450-2456.
2Kris M, Natale RB, Herbst R, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non small cell lung cancer [J]. JAMA, 2003,290:2149-2158.
3Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2003, 21 (12) : 2237-2246.
4Ochs J, Grous J J, Warner KL, et al. Final survival and safety results for 21064 non-small-cell lung cancer patients who received compassonate use gefitinib in a u. s. expanded access program[J]. Proc Am Soc Clin Oncol, 2004,23 :628.
5Takano T, Ohe Y, Kusumoto M,et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with non-small-cell lung cancer treated with gefitinib[J]. Lung Cancer, 2004,45(1): 93- 104.
6Kim KS, Jeong JY, Kim YC,et al. Predictors of the response to gefitinib in refractory non-small-cell lung cancer[J]. Clin Cancer Res, 2005,11 (6):2244-2251.
7West H, Franklin WA, Gumerlock PH, et al. Gefitinib (ZD1839) therapy for advanced brochioalverlar lung cancer (BAC) : Southwest Oncology Group (SWOG) Study S0126[J]. Proc Am Soc Clin Oncol, 2004,23:618.
8Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised placebo-controlled, multicentre study (Iressa Survival Evalua tion in Lung Cancer)[J]. Lancet,2005,366: 1527-1537.
9Ishida A, Kanoh K, Nishisaka T, et al. Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases [J]. Internal Medicine, 2004,43(8) :718-720.
10Okamoto T, Nakamura T, Ikeda J, et al. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer[J]. European Journal of Cancer, 2005,41 (9) :1286-1290.
